Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07544654 Etoposide Advanced Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07544654 clinical trial report covering Etoposide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07549386 Diacerein Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07549386 clinical trial report covering Diacerein, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07551544 Bacillus Calmette-Guerin(ImmunityBio) Non-Muscle Invasive Bladder Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07551544 clinical trial report covering Bacillus Calmette-Guerin(ImmunityBio), Phase 3, endpoints, sponsor, geography, readout timing and development wh
Read →
Latest Hotspot
8 min read
ChiCTR2600124664 Obefazimod Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600124664 clinical trial report covering Obefazimod, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
ChiCTR2600125501 Ticagrelor Cerebrovascular Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600125501 clinical trial report covering Ticagrelor, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07564726 Amlodipine Besylate Primary hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07564726 clinical trial report covering Amlodipine Besylate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07593924 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences) Pneumococcal Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07593924 clinical trial report covering 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences), Phase 3, endpoints, sponsor, geo
Read →
Latest Hotspot
8 min read
NCT07563634 Brivaracetam Epilepsies, Partial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07563634 clinical trial report covering Brivaracetam, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
8 min read
CRLF1 Biologics Sequence Review Report 2026: Cytokine receptor-like factor 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CRLF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
C1QTNF9B Biologics Sequence Review Report 2026: Complement C1q and tumor necrosis factor-related protein 9B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF9B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CR1L Biologics Sequence Review Report 2026: Complement component receptor 1-like protein Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CR1L protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
C1QTNF7 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 7 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
165
166
167
168
169
>>
1670
>